VIBERZI Drug Safety Podcast

FDA Logo, hands holding pills

FDA review shows increased risk of serious pancreatitis in patients without a gallbladder

Prescribed to treat irritable bowel syndrome with diarrhea (IBS-D)
Patients, without a gallbladder, have increased risk of developing serious pancreatitis that could result in hospitalization or death
Pancreatitis caused by spasm of certain digestive system muscle in the small intestine
FDA working with manufacturer, Allergan, to address safety concerns

Published by Drug & Device Advisory Group

Enter your comment here…

Fill in your details below or click an icon to log in:

Email (required) (Address never made public)

Name (required)

Website

You are commenting using your WordPress.com account.
( Log Out /
Change )

You are commenting using your Google account.
( Log Out /
Change )

You are commenting using your Twitter account.
( Log Out /
Change )

You are commenting using your Facebook account.
( Log Out /
Change )

Connecting to %s